Scienture (SCNX) Competitors $7.58 -0.55 (-6.77%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends SCNX vs. URGN, AVIR, CMRX, RZLT, ABEO, MRSN, HRTX, RENB, FULC, and DMACShould you be buying Scienture stock or one of its competitors? The main competitors of Scienture include UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), Chimerix (CMRX), Rezolute (RZLT), Abeona Therapeutics (ABEO), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), Renovaro (RENB), Fulcrum Therapeutics (FULC), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical preparations" industry. Scienture vs. UroGen Pharma Atea Pharmaceuticals Chimerix Rezolute Abeona Therapeutics Mersana Therapeutics Heron Therapeutics Renovaro Fulcrum Therapeutics DiaMedica Therapeutics Scienture (NASDAQ:SCNX) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Do insiders & institutionals believe in SCNX or URGN? 5.7% of Scienture shares are held by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are held by institutional investors. 29.1% of Scienture shares are held by insiders. Comparatively, 5.1% of UroGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer SCNX or URGN? In the previous week, Scienture had 1 more articles in the media than UroGen Pharma. MarketBeat recorded 1 mentions for Scienture and 0 mentions for UroGen Pharma. Scienture's average media sentiment score of 0.99 beat UroGen Pharma's score of 0.00 indicating that Scienture is being referred to more favorably in the media. Company Overall Sentiment Scienture Positive UroGen Pharma Neutral Does the MarketBeat Community believe in SCNX or URGN? UroGen Pharma received 365 more outperform votes than Scienture when rated by MarketBeat users. CompanyUnderperformOutperformScientureN/AN/AUroGen PharmaOutperform Votes36573.89% Underperform Votes12926.11% Which has more risk and volatility, SCNX or URGN? Scienture has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Do analysts recommend SCNX or URGN? UroGen Pharma has a consensus price target of $43.70, indicating a potential upside of 310.71%. Given UroGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe UroGen Pharma is more favorable than Scienture.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has stronger valuation and earnings, SCNX or URGN? Scienture has higher earnings, but lower revenue than UroGen Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScienture$7.12M9.13-$17.84MN/AN/AUroGen Pharma$89.36M2.79-$102.24M-$3.15-3.38 Is SCNX or URGN more profitable? Scienture has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Scienture's return on equity.Company Net Margins Return on Equity Return on Assets ScientureN/A -77.60% -62.29% UroGen Pharma -129.11%N/A -47.94% SummaryUroGen Pharma beats Scienture on 9 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Scienture News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNX vs. The Competition Export to ExcelMetricScienturePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.01M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.1317.19Price / Sales9.13196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book16.845.094.784.78Net Income-$17.84M$151.83M$120.31M$225.60M7 Day Performance1.47%-2.14%-1.92%-1.23%1 Month Performance0.53%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Scienture Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNXScientureN/A$7.58-6.8%N/AN/A$65.01M$7.12M0.00N/AGap DownURGNUroGen Pharma3.8807 of 5 stars$11.30-0.4%$43.70+286.7%-29.4%$265.03M$89.36M-3.59200AVIRAtea Pharmaceuticals3.0724 of 5 stars$3.10+5.8%$6.88+121.9%+1.6%$261.84M$351.37M-1.5070High Trading VolumeCMRXChimerix4.2942 of 5 stars$2.91-1.4%$8.50+192.1%+225.0%$261.73M$320,000.00-3.1072RZLTRezolute3.1771 of 5 stars$4.49-2.2%$24.13+437.3%+388.2%$260.16MN/A-3.5440Positive NewsABEOAbeona Therapeutics3.5948 of 5 stars$5.89flat$18.00+205.6%+19.2%$256.04M$3.50M-2.19N/AAnalyst UpgradeMRSNMersana Therapeutics4.3171 of 5 stars$2.07-3.7%$6.00+189.9%-17.5%$255.71M$34.84M-3.39150Gap DownHRTXHeron Therapeutics3.9502 of 5 stars$1.68+5.0%$5.67+237.3%-9.2%$255.52M$137.74M-9.33300Analyst DowngradeGap DownRENBRenovaro1.1744 of 5 stars$1.58-10.2%N/A-50.9%$250.77MN/A-1.6512News CoverageGap UpFULCFulcrum Therapeutics1.7128 of 5 stars$4.42+11.6%$9.33+111.2%-24.6%$238.41M$80.87M-14.26100Positive NewsDMACDiaMedica Therapeutics0.8091 of 5 stars$5.31-1.3%$7.00+31.8%+127.3%$227.06MN/A-9.4820News CoverageGap Down Related Companies and Tools Related Companies URGN Competitors AVIR Competitors CMRX Competitors RZLT Competitors ABEO Competitors MRSN Competitors HRTX Competitors RENB Competitors FULC Competitors DMAC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCNX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
